🇺🇸 Autologous serum in United States
32 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 32
Most-reported reactions
- Eye Pain — 9 reports (28.12%)
- Drug Ineffective — 3 reports (9.38%)
- Lacrimation Increased — 3 reports (9.38%)
- Ocular Discomfort — 3 reports (9.38%)
- Periorbital Pain — 3 reports (9.38%)
- Photophobia — 3 reports (9.38%)
- Diarrhoea — 2 reports (6.25%)
- Eye Irritation — 2 reports (6.25%)
- Eye Swelling — 2 reports (6.25%)
- Eyelid Ptosis — 2 reports (6.25%)
Other Ophthalmology approved in United States
Frequently asked questions
Is Autologous serum approved in United States?
Autologous serum does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Autologous serum in United States?
Anita Syla Lokaj is the originator. The local marketing authorisation holder may differ — check the official source linked above.